HBRM.US Herborium Group Inc
- Market cap
- USD 1.09M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Aug 2026.
Is HBRM.US undervalued?
Graham numberThe Graham number of Herborium Group Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Herborium Group Inc fundamental analysis
No fundamental analysis for Herborium Group Inc yet.
Herborium Group Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Herborium Group Inc
Herborium Group, Inc., a botanical therapeutics company, develops, licenses, and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The company offers dermatology products, which include AcnEase, an herbal medicinal product for enhancing conditions associated with hormonal acne and multiple symptoms of Rosacea; and AcnEase Skin Management System for the treatment of acne marks/scars. The company sells its products in the United…
Full company profileHerborium Group Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Herborium Group Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 843K | 909K | 816K | 875K | 994K | 1.05M | 1.13M | 1.12M | 1.05M | 788K | 511K |
| Gross Profit | 530K | 560K | 478K | 510K | 639K | 662K | 702K | 624K | 662K | 497K | 261K |
| Operating Income | 3.40K | 34.9K | -86.3K | -54.0K | 68.7K | -288K | -267K | 28.7K | -288K | -238K | -102K |
| EBITDA | 9.40K | 40.9K | -80.3K | -48.0K | 74.7K | -282K | -263K | 197K | -288K | -238K | -102K |
| Net Income | -54.7K | -32.2K | -174K | -76.0K | 47.1K | -329K | -267K | 29.5K | -329K | -155K | -146K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 173K | 188K | 230K | 173K | 207K | 170K | 175K | 156K | 157K | 143K | 118K |
| Total Liabilities | 446K | 552K | 710K | 729K | 710K | 4.00M | 4.13M | 4.47M | 4.11M | 4.11M | 4.11M |
| Shareholders' Equity | -273K | -365K | -479K | -555K | -503K | -3.83M | -3.96M | -4.32M | -4.30M | -4.30M | -4.30M |
| Cash & Short-term Investments | 8.40K | 3.70K | 8.60K | 6.00K | 13.5K | 8.00K | 13.5K | 10.3K | 10.3K | 5.13K | 2.55K |
| Total Debt | 407K | 325K | 322K | 329K | 405K | 1.05M | 1.05M | 1.07M | 1.07M | 1.07M | 868K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 8.80K | 79.6K | -118K | -71.0K | -43.4K | 94.1K | -133K | 370K | - | - | -22.4K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.1K | 1.60K | 1.85K | - | - | 0.00 |
| Free Cash Flow | 8.80K | 79.6K | -118K | -71.0K | -43.4K | 94.1K | -135K | 368K | - | - | -22.4K |
| Ratios | |||||||||||
| ROA | -31.5% | -17.2% | -75.8% | -43.9% | 22.8% | -193.4% | -152.5% | 18.9% | -209.1% | -108.4% | -124.4% |
| Net Profit Margin | -6.5% | -3.5% | -21.3% | -8.7% | 4.7% | -31.3% | -23.6% | 2.6% | -31.3% | -19.6% | -28.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Herborium Group Inc dividends
Herborium Group Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:1000 on Jan 27, 2014.
Who owns Herborium Group Inc
Ownership data of Herborium Group Inc is not available yet.
Herborium Group Inc company profile
- Company name
- Herborium Group Inc
- Ticker
- HBRM.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Personal Care Products
- Employees
- 2
- Fiscal year end
- November
- Address
- 14090 Southwest Freeway, Sugar Land, TX, United States, 77478
- Phone
- 201-647-3757
- Website
- herborium.com
About Herborium Group Inc
Herborium Group, Inc., a botanical therapeutics company, develops, licenses, and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The company offers dermatology products, which include AcnEase, an herbal medicinal product for enhancing conditions associated with hormonal acne and multiple symptoms of Rosacea; and AcnEase Skin Management System for the treatment of acne marks/scars. The company sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. The company is headquartered in Sugar Land, Texas.
Herborium Group Inc management
6- Dr. Agnes P. Olszewski MBA, Ph.D.Founder, Chairman, CEO, President, CFO & Principal Accounting Officer · born 1957
- Dr. James P. Gilligan MSIB, Ph.D.Co-Founder, Scientific Advisor & Director · born 1952
- Mr. Daniel TeoSenior Vice President of Business Development
- Mr. Lawrence WooAsia Business Advisor & Director
- Mr. Roger Jones OBEUK & EU Advisor and Director · born 1943
- Mr. John E. DonahueController & SEC Advisor · born 1950